A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database.

ABSTRACT:

Background

Tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults with obesity or overweight as an adjunct to a reduced-calorie diet and increased physical activity. However, the safety profile of Tirzepatide-associated adverse events requires comprehensive evaluation.

Methods

The AE reports from the first quarter of 2022 to the third quarter of 2023 were selected by exploring the FDA Adverse Event Reporting System (FAERS) database. The new and unexpected potenial AE signals were detected using the disproportionality analysis, including reporting odds ratio(ROR), the proportional reporting ratio (PRR) the Bayesian confidence propagation neural networ

SUBMITTER: Liu L 

PROVIDER: S-EPMC11190169 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature